Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins)

British Journal of Pharmacology

Volumn 133, Issue 7, 2001, Pages 1172-1180

  Eberlein, Michael ^a   Heusinger Ribeiro, Juliane ^a   Goppelt Struebe, Margarete ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Connective tissue growth factor; HMG CoA reductase; Lovastatin; Lysophosphatidic acid; Rho protein; Simvastatin; Transforming growth factor

Indexed keywords

ACTIN; CONNECTIVE TISSUE GROWTH FACTOR; ENZYME INHIBITOR; FARNESYL DIPHOSPHATE; FARNESYL TRANS TRANSFERASE; GTI 286; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYSOPHOSPHATIDIC ACID; MESSENGER RNA; MEVINOLIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; PRAVASTATIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RHO FACTOR; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MEMBRANE BINDING; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ACTINS; BLOTTING, NORTHERN; CELL LINE; CYTOSKELETON; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GROWTH SUBSTANCES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LOVASTATIN; LYSOPHOSPHOLIPIDS; MEVALONIC ACID; POLYISOPRENYL PHOSPHATES; PRAVASTATIN; RHO GTP-BINDING PROTEINS; RHOA GTP-BINDING PROTEIN; RNA, MESSENGER; SIMVASTATIN;

EID: 0034888856     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704173     Document Type: Article

References (52)

1. Transforming growth factor-beta in renal disease
2. The modular architecture of a new family of growth regulators related to connective tissue growth factor
3. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
4. Lysophosphatidic acid receptors
5. Connective tissue growth factor: A novel regulator of mucosal repair and fibrosis in inflammatory bowel disease?
6. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
7. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: Down-regulation by cAMP
8. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: Role of geranylgeranylation and Rho proteins
9. Connective tissue growth factor expression in the rat remnant kidney model and association with tubular epithelial cells undergoing transdifferentiation
10. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor
11. Inhibition of protein isoprenylation impairs rho-regulated early cellular response to genotoxic stress
12. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysopho-sphatidic acid and sphingosine 1-phosphate
13. The platelet-derived-growth-factor receptor, not the epidermal-growth-factor receptor, is used by lysophosphatidic acid to activate p42/44 mitogen-activated protein kinase and to induce prostaglandin G/H synthase-2 in mesangial cells
14. Connective tissue growth factor: A mediator of TGF-beta action on fibroblasts
15. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene
16. Connective tissue growth factor: Potential role in glomerulosclerosis and tubulointerstitial fibrosis
17. Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by rho proteins and the actin cytoskeleton
18. Lysophosphatidic acid-induced expression of connective tissue growth factor in human renal fibroblasts: Regulatory role of RhoA and cAMP
19. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders
20. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin
21. Expression of connective tissue growth factor in human renal fibrosis
22. Cell cycle-specific effects of lovastatin
23. In vitro effects of simvastatin on tubulointerstitial cells in a human model of cyclosporin nephrotoxicity
24. The role of lipids in renal disease: Future challenges
25. Lovastatin inhibits transforming growth factor-beta 1 expression in diabetic rat glomeruli and cultured rat mesangial cells
26. Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin
27. Role of Rho proteins in lovastatin-induced breakdown of actin cytoskeleton
28. Transforming growth factor beta induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor- dependent signaling pathway
29. TGF-beta1 stimulation of fibronectin transcription in cultured human lung fibroblasts requires active geranylgeranyl transferase I, phosphatidylcholine-specific phospholipase C, protein kinase C-delta, and p38, but not erk1/erk2
30. The CCN family of angiogenic regulators: The integrin connection
31. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription
32. Inhibition of Ras prenylation: A signaling target for novel anti-cancer drug design
33. Current perspectives on statins
34. High glucose induces the expression of connective tissue growth factor in human mesangial cells
35. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: Effects of oxidation and modulation by lovastatin
36. Prevention of progression of renal fibrosis: How far are we?
37. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells
38. Human renal fibroblast cell lines (tFKIF and tNKF) are new tools to investigate pathophysiologic mechanisms of renal interstitial fibrosis
39. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types
40. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions
41. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats
42. Transcriptional regulation of connective tissue growth factor by cortisol in osteoblasts
43. Specificity, diversity, and regulation in TGF-beta superfamily signaling
44. Gprotein-mediated signaling in cholesterol-enriched arterial smooth muscle cells. I. Reduced membrane-associated G-protein content due to diminished isoprenylation of G-gamma subunits and p21 ras
45. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells
46. Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I
47. Signal transduction pathways responsible for serotonin-mediated prostaglandin G/H synthase expression in rat mesangial cells
48. Rho GTPases and signaling networks
49. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21 ras activated, AP-1-dependent pathway
50. Effect of lipid-lowering strategies on tubular cell biology
51. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin AT1 receptor expression and RacI GTPase
52. Protein prenylation: Molecular mechanisms and functional consequences